白介素2联合胸腺肽α1对肝癌术后患者肝纤维化指标和肝功能的影响

Effect of interleukin-2 and thymosin α1 on liver fibrosis markers and liver function in liver patients undergoing

目的:探讨白介素2联合胸腺肽α1对肝癌术后患者肝纤维化指标及肝功能的影响。方法:将72例在我院实施肝癌手术的患者按照随机数字法分为对照组(单用胸腺肽α1)与观察组(胸腺肽α1联用白介素2)各36例,比较给药前及给药后两组患者肝功能、肝纤维化指标、AFP表达量的差异,并对患者治疗6个月后复发率及生存率进行比较。结果:观察组ALT、AST、TBIL、ALB 4项肝功能指标及HA、LN、PCⅢ、CⅣ4项肝纤维化指标的改善效果均优于对照组(P<0.05),AFP值也低于对照组(P<0.05),但生存率及复发率两组差异无统计学意义(P>0.05)。结论:白介素2联用胸腺肽α1有助于改善肝癌术后患者肝功能,降低肝纤维化程度及AFP表达水平,具有一定的临床应用价值。

Objective： To discuss the effect of interleukin-2 and thymosin α1 on liver cancer patients liver fibrosis and liver function. Methods： The implementation of patients with Liver Cancer in our hospital,according to randomized into the control group（ n = 36） and observation group（ n = 36）,in which the control group with conventional chemotherapy drugs thymosin α1 injection,observation group with conventional chemotherapy drugs thymosin α1 and interleukin 2. The two groups were compared before and after administration of the administration two weeks liver function,liver fibrosis,AFP expression of differences,and patients relapse after 6 months of treatment and survival rate rates were compared. Results： Observer group in liver function（ ALT,AST,TPIL,ALB） liver fibrosis index（ HA,LN,PCⅢ,CⅣ） and improvement effect was better than the control group（ P 〈0. 05）; in addition,the two groups in the expression of AFP comparison,the observation group was lower than the control group（ P 〈 0. 05）,but there was no significant difference（ P 〉 0. 05） on survival and recurrence rate（ P 〉0. 05）. Conclusion： Interleukin-2 combined with thymosin α1 can improve liver function of liver cancer patients,and reduce liver fibrosis and AFP expression level,with certain clinical value.